Analysts forecast that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will report $4.66 million in sales for the current fiscal quarter, according to Zacks. Nine analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings. The highest sales estimate is $13.35 million and the lowest is $2.00 million. The firm is scheduled to issue its next earnings report on Thursday, July 26th.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year sales of $33.51 million for the current fiscal year, with estimates ranging from $22.80 million to $65.93 million. For the next financial year, analysts expect that the company will post sales of $84.48 million per share, with estimates ranging from $58.30 million to $104.26 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Monday, May 7th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.81. The firm had revenue of $10.68 million during the quarter, compared to analyst estimates of $56.58 million. During the same quarter in the prior year, the business earned ($1.63) earnings per share.
In other news, VP Theodore Alan Huizenga sold 955 shares of the firm’s stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $83.70, for a total transaction of $79,933.50. Following the completion of the transaction, the vice president now directly owns 12,895 shares of the company’s stock, valued at approximately $1,079,311.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Karah Herdman Parschauer sold 1,465 shares of the firm’s stock in a transaction that occurred on Thursday, May 10th. The stock was sold at an average price of $60.00, for a total transaction of $87,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 31,003 shares of company stock valued at $2,275,942 over the last ninety days. Company insiders own 8.40% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 1,246.9% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,273 shares of the biopharmaceutical company’s stock worth $152,000 after acquiring an additional 3,030 shares in the last quarter. Kornitzer Capital Management Inc. KS bought a new position in shares of Ultragenyx Pharmaceutical in the first quarter valued at $3,687,000. Paloma Partners Management Co bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at $580,000. Swiss National Bank grew its stake in shares of Ultragenyx Pharmaceutical by 4.0% in the fourth quarter. Swiss National Bank now owns 69,952 shares of the biopharmaceutical company’s stock valued at $3,244,000 after buying an additional 2,700 shares in the last quarter. Finally, Prosight Management LP bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at $2,069,000. 96.03% of the stock is owned by institutional investors.
Shares of NASDAQ:RARE traded down $4.72 during mid-day trading on Friday, reaching $79.54. The stock had a trading volume of 472,700 shares, compared to its average volume of 560,017. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of -10.61 and a beta of 1.97. Ultragenyx Pharmaceutical has a twelve month low of $41.67 and a twelve month high of $86.10.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.